Verona's Ensifentrine: A Promising Novel Treatment For COPD Patients
Seeking Alpha,
Follow Summary Verona Pharma's ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes PDE3 and PDE4…
Follow Summary Verona Pharma's ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes PDE3 and PDE4…
Ensifentrine improves lung function and quality of life when added to maintenance tiotropium LONDON and RALEIGH, N.C., April 27…
By: GlobenewsWire - 27 Apr 2021 Ensifentrine improves lung function and quality of life when added to maintenance tiotropium…
LONDON and RALEIGH, N.C., April 27, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage…